The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent cannabis use. Other pharmacodynamic effects of inhaled cannabis with CBD and THC will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
22
University of California, Los Angeles
Los Angeles, California, United States
RECRUITINGSubjective drug effect ratings of impairment and abuse liability
Peak subjective ratings of drug effects associated with abuse liability and impairment as measured using visual analogue scales (VAS; 1-100mm).
Time frame: 6 hours
Pharmacokinetics of THC, CBD and metabolites
Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH after exposure (Tmax)
Time frame: 6 hours
Behavioral task performance as assessed by the DRUID App Score
Trough composite scores on the DRUID App
Time frame: 6 hour
THC concentrations in oral fluid
Peak levels of THC in oral fluid after exposure
Time frame: 6 hour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Smoked cannabis with THC